Company intelligence / Profile preview

UltraShape Medical

Yokneam, Israel

Ownership: Private
Development stage: Other

Overview

UltraShape developed non-invasive focused ultrasound technology for fat cell destruction. Their products, including UltraShape Power, are FDA-cleared for abdominal and flank fat reduction and commercially available. Clinically proven with over 350,000 treatments worldwide, the technology targets adipocytes for body contouring, showing significant circumferential reductions (e.g., 94% of patients in a 150-subject trial).

Therapeutic areas: NephrologyOtherMetabolic Disorders
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on UltraShape Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UltraShape Medical.

Explore the full profile